肾AA淀粉样变性:表现、诊断及当前治疗选择:综述
本文综述肾AA淀粉样变性的表现、诊断与治疗。该病为血清淀粉样A蛋白沉积所致,肾脏最常受累,多表现为蛋白尿和肾衰竭,诊断依靠组织活检。治疗主要针对原发病,并越来越多使用白介素-1、白介素-6及肿瘤坏死因子-α抑制剂阻断炎症级联以减少血清淀粉样A蛋白形成,该策略对原发病不明者亦显示疗效并显著改善预后。
要点
- 肾AA淀粉样变性是仅次于单克隆Ig相关淀粉样变性的第二常见系统性淀粉样变性。
- 肾脏是最常受累器官,多数患者表现为蛋白尿和肾衰竭。
- 诊断依靠组织活检,多数病例累及肾小球,也常累及血管和肾小管间质。
核心结论
- 阻断炎症细胞因子级联以减少血清淀粉样A蛋白形成的策略已显著改善该病预后,对原发病不明者亦显示疗效。
- 开发清除组织淀粉样沉积的有效疗法受到越来越多关注,但迄今结果有限。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 肾AA淀粉样变性是系统性淀粉样变性的第二常见形式,仅次于单克隆Ig相关淀粉样变性。
- 该病由血清淀粉样A蛋白来源的不溶性纤维在组织细胞外空间沉积所致,血清淀粉样A蛋白是在慢性炎症时过度合成的急性期反应物。
- 肾脏是最常受累器官,多数患者表现为蛋白尿和肾衰竭。
- 诊断通过组织活检,多数病例累及肾小球,也常累及血管和肾小管间质。
- 治疗通常针对原发病,并越来越多使用白介素-1抑制剂、白介素-6抑制剂和肿瘤坏死因子-α抑制剂阻断炎症细胞因子级联以减少血清淀粉样A蛋白形成。
临床怎么用
- 治疗通常针对原发病,并越来越多使用白介素-1抑制剂、白介素-6抑制剂和肿瘤坏死因子-α抑制剂阻断炎症细胞因子级联以减少血清淀粉样A蛋白形成。
- 该策略对原发病无法明确识别的病例也显示出疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyloid A amyloidosis is thought to be the second most common form of systemic amyloidosis behind amyloidosis secondary to monoclonal Ig. It is the result of deposition of insoluble fibrils in the extracellular space of tissues and organs derived from the precursor protein serum amyloid A, an acute phase reactant synthesized excessively in the setting of chronic inflammation. The kidney is the most frequent organ involved. Most patients present with proteinuria and kidney failure. The diagnosis is made through tissue biopsy with involvement of the glomeruli in most cases, but also often of the vessels and the tubulointerstitial compartment. The treatment usually targets the underlying etiology and consists increasingly of blocking the inflammatory cascade of cytokines with interleukin-1 inhibitors, interleukin-6 inhibitors, and tumor necrosis factor-α inhibitors to reduce serum amyloid A protein formation. This strategy has also shown efficacy in cases where an underlying etiology cannot be readily identified and has significantly improved the prognosis of this entity. In addition, there has been increased interest at developing effective therapies able to clear amyloid deposits from tissues, albeit with mitigated results so far.
引用
- Karam S, Haidous M, Royal V, et al. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2022. PMID: 36502873. doi:10.1016/j.kint.2022.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。